Turning Point Therapeutics Inc logo

TPTX

Turning Point Therapeutics Inc

$76.01

Earnings Summary

Net Profits
$-20.96Mn

Highlights

Net Profits:

Turning Point Therapeutics Inc’s net profit fell -132.41% since last year same period to $-20.96Mn in the Q4 2019. On a quarterly growth basis, Turning Point Therapeutics Inc has generated -2.32% fall in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Turning Point Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.7
EPS Estimate Current Year
-1.7

Highlights

EPS Estimate Current Quarter:

Turning Point Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.7 - a -12.58% fall from last quarter’s estimates.

EPS Estimate Current Year:

Turning Point Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.7.

Key Ratios

Key ratios of the Turning Point Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-1.5
Return on Assets (ROA)
-0.14
Return on Equity (ROE)
-0.23

Highlights

Earning Per Share (EPS):

Turning Point Therapeutics Inc’s earning per share (EPS) fell -105.48% since last year same period to -1.5 in the Q1 2022. This indicates that the Turning Point Therapeutics Inc has generated -105.48% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Turning Point Therapeutics Inc’s return on assets (ROA) stands at -0.14.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Turning Point Therapeutics Inc’s return on equity (ROE) stands at -0.23.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-1.51
-1.5
0.66%

Company Information

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing and developing therapies that target genetic drivers of cancer to improve the lives of patients. It develops a macrocycle platform from which it designs its pipeline of small, compact tyrosine kinase inhibitors (TKIs). The TKIs generated from its drug discovery platform address unmet needs in TKI naive and resistance settings. The Company’s drug candidate, repotrectinib (TPX-0005), is in Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with NTRK+ or ALK+ advanced solid tumors. Its multi-cohort Phase II registrational portion of TRIDENT-1 is ongoing at sites in North America, Europe and the Asia-Pacific regions. The Company’s pipeline includes multi-targeted kinase inhibitors: TPX-0046 (a novel RET inhibitor), Elzovantinib (TPX-0022) (a novel MET/CSF1R/SRC inhibitor) and TPX-0131.

Organisation
Turning Point Therapeutics Inc

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*